A recent phase II trial with cisplatin-resistant or cetuximab-resistant HPV(-) HNSCC patients treated with a CDK4/6 inhibitor, palbociclib, and cetuximab results in promising activity outcomes [135]. The gene discussed is CDK4; the disease is head and neck squamous cell carcinoma.